Syneron Medical Ltd. (NASDAQ:ELOS) shares were up 3.1% during mid-day trading on Monday . The company traded as high as $6.64 and last traded at $6.64, with a volume of 56,041 shares. The stock had previously closed at $6.44.

A number of research analysts recently issued reports on ELOS shares. Leerink Swann downgraded shares of Syneron Medical from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $9.40 to $7.80 in a research note on Friday, August 5th. Zacks Investment Research upgraded shares of Syneron Medical from a “sell” rating to a “hold” rating in a research report on Monday, July 25th. Finally, Brean Capital restated a “buy” rating on shares of Syneron Medical in a research report on Thursday, June 16th.

The firm has a 50 day moving average of $7.04 and a 200 day moving average of $7.16. The company’s market capitalization is $233.87 million.

Syneron Medical (NASDAQ:ELOS) last released its quarterly earnings results on Thursday, August 4th. The company reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.03. During the same period in the previous year, the business posted $0.07 EPS. The company had revenue of $75 million for the quarter, compared to analyst estimates of $75.72 million. The firm’s quarterly revenue was up 2.0% compared to the same quarter last year. Analysts expect that Syneron Medical Ltd. will post $0.27 earnings per share for the current fiscal year.

Syneron Medical Ltd. is engaged in the manufacture, research, development, marketing and sale of equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company designs, develops and markets aesthetic medical products based on its various technologies, including Electro-Optical Synergy (ELOS) technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.